key: cord-0078514-rpjqjiyj
authors: Benotmane, Ilies; Velay, Aurélie; Vargas, Gabriela Gautier; Olagne, Jérôme; Thaunat, Olivier; Fafi-Kremer, Samira; Caillard, Sophie
title: Pre-exposure prophylaxis with 300 mg Evusheld™ elicits limited neutralizing activity against the Omicron variant
date: 2022-05-24
journal: Kidney Int
DOI: 10.1016/j.kint.2022.05.008
sha: b1b0f0c2f6c0944c9be6ca968719e6f36bfbe161
doc_id: 78514
cord_uid: rpjqjiyj

nan

Immunocompromised patients show an impaired vaccine-induced immune response, resulting in an increased risk of severe Covid-19 (1) . In an effort to address this issue, health authorities in the US and various European countries have subsequently authorized the use of anti-SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis. While the combination of casirivimab-imdevimab (Ronapreve™, Roche Regeneron) has been shown to confer satisfactory protection against the delta variant, it has limited neutralizing activity against omicron (3). In March 2022, the combination of cilgavimab-tixagevimab (Evusheld™, Astra Zeneca) has been approved in the UK for protecting transplant recipients with poor response to vaccination against the omicron variant (3). In France, Evusheld™ has also been granted approval as of December 2021. While the PROVENT study (Phase III Double-blind, Placebocontrolled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult) showed a good efficacy of 300 mg Evusheld™ in the context of delta variant circulation, the question as to whether this dosage may be sufficient to prevent the omicron infection remains unanswered. Previous data indicated that the serum neutralizing capacity against SARS-CoV-2 is positively associated with protection against severe forms of Covid-19 (4). Here, we analyzed the neutralizing capacity against omicron in a cohort of kidney transplant recipients who received Evusheld™ for pre-exposure prophylaxis. figure   1B ). This variability was largely explained by the patients' body mass index, which showed an inverse correlation with anti-RBD IgG titers (Figure 1c ). Further analysis revealed that participants with anti-RBD titers <2500 BAU/mL after Evusheld™ injection had no neutralizing activity ( Figure 2) . Furthermore, seven patients of this cohort developed symptomatic Covid-19 including two who required hospitalization. All had negative neutralizing activity at the time of infection diagnosis.

Taken together, these data indicate that less than 10% of patients who received Evusheld™ were able to neutralize the omicron BA.1 variant at 29 post-injection days. Therefore, the dose of 300 mg Evusheld™ is likely insufficient to achieve the required neutralization activity in vivo. These findings corroborate those of a recent study conducted in transplant recipients who received three vaccine doses (5); specifically, the authors reported that anti-RBD levels associated with serum neutralizing activity against omicron in this population were approximately 8500 BAU/mL (5) . Finally, our study also supports recent FDA recommendations (6), derived from in vitro models, regarding the need to increase the dose of 

Correlation between body mass index (kg/m 2 ) and anti-RBD IgG titers (BAU/mL, Abbott Architect, Chicago, IL, USA) 28 days after Evusheld™ injection (300 mg) in 27 patients who did not receive Ronapreve™ before Evusheld™; r 2 =0.595. 

COVID-19 vaccination in kidney transplant recipients

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients

Neutralization against Omicron variant in transplant recipients after three-doses of mRNA vaccine

Epub ahead of print